Acorda Therapeutics Inc (ACOR) Major Shareholder Sells $595,728.96 in Stock

Share on StockTwits

Acorda Therapeutics Inc (NASDAQ:ACOR) major shareholder Scopia Capital Management Lp sold 20,256 shares of the business’s stock in a transaction on Tuesday, August 28th. The stock was sold at an average price of $29.41, for a total transaction of $595,728.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Scopia Capital Management Lp also recently made the following trade(s):

  • On Thursday, September 6th, Scopia Capital Management Lp sold 13,829 shares of Acorda Therapeutics stock. The stock was sold at an average price of $27.82, for a total transaction of $384,722.78.
  • On Tuesday, September 4th, Scopia Capital Management Lp sold 200 shares of Acorda Therapeutics stock. The stock was sold at an average price of $29.00, for a total transaction of $5,800.00.
  • On Monday, July 23rd, Scopia Capital Management Lp sold 25,000 shares of Acorda Therapeutics stock. The stock was sold at an average price of $28.32, for a total transaction of $708,000.00.
  • On Wednesday, July 25th, Scopia Capital Management Lp sold 86,551 shares of Acorda Therapeutics stock. The stock was sold at an average price of $28.61, for a total transaction of $2,476,224.11.
  • On Friday, July 20th, Scopia Capital Management Lp sold 108,740 shares of Acorda Therapeutics stock. The stock was sold at an average price of $29.09, for a total transaction of $3,163,246.60.
  • On Friday, July 13th, Scopia Capital Management Lp sold 100 shares of Acorda Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $3,000.00.
  • On Tuesday, July 17th, Scopia Capital Management Lp sold 33,299 shares of Acorda Therapeutics stock. The stock was sold at an average price of $30.04, for a total transaction of $1,000,301.96.
  • On Tuesday, July 10th, Scopia Capital Management Lp sold 200,354 shares of Acorda Therapeutics stock. The stock was sold at an average price of $30.61, for a total transaction of $6,132,835.94.
  • On Thursday, July 5th, Scopia Capital Management Lp sold 27,093 shares of Acorda Therapeutics stock. The stock was sold at an average price of $30.10, for a total transaction of $815,499.30.
  • On Monday, July 2nd, Scopia Capital Management Lp sold 35,889 shares of Acorda Therapeutics stock. The stock was sold at an average price of $30.06, for a total transaction of $1,078,823.34.

NASDAQ ACOR traded down $0.45 on Friday, hitting $27.35. 6,127 shares of the stock were exchanged, compared to its average volume of 322,227. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.56. Acorda Therapeutics Inc has a 52 week low of $16.55 and a 52 week high of $36.35. The firm has a market capitalization of $1.34 billion, a P/E ratio of 26.73 and a beta of 1.46.

Acorda Therapeutics (NASDAQ:ACOR) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.90. Acorda Therapeutics had a negative net margin of 26.87% and a positive return on equity of 8.19%. The firm had revenue of $153.30 million for the quarter, compared to analyst estimates of $138.63 million. During the same period in the prior year, the firm posted $0.29 earnings per share. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. research analysts anticipate that Acorda Therapeutics Inc will post -0.09 EPS for the current fiscal year.

ACOR has been the topic of a number of research reports. BidaskClub lowered shares of Acorda Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 10th. HC Wainwright set a $31.00 price objective on shares of Acorda Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, May 30th. ValuEngine raised shares of Acorda Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 8th. Oppenheimer set a $21.00 price objective on shares of Acorda Therapeutics and gave the stock a “hold” rating in a research report on Monday, June 11th. Finally, TheStreet raised shares of Acorda Therapeutics from a “d+” rating to a “c-” rating in a research report on Tuesday, June 19th. One analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $24.69.

Several institutional investors and hedge funds have recently modified their holdings of ACOR. Rhumbline Advisers raised its position in shares of Acorda Therapeutics by 2.1% in the first quarter. Rhumbline Advisers now owns 110,279 shares of the biopharmaceutical company’s stock valued at $2,608,000 after purchasing an additional 2,268 shares during the period. Mackay Shields LLC bought a new position in shares of Acorda Therapeutics in the first quarter valued at about $486,000. Trexquant Investment LP bought a new position in shares of Acorda Therapeutics in the first quarter valued at about $686,000. Prudential Financial Inc. raised its position in shares of Acorda Therapeutics by 28.5% in the first quarter. Prudential Financial Inc. now owns 309,014 shares of the biopharmaceutical company’s stock valued at $7,309,000 after purchasing an additional 68,626 shares during the period. Finally, Aperio Group LLC raised its position in shares of Acorda Therapeutics by 18.1% in the first quarter. Aperio Group LLC now owns 15,709 shares of the biopharmaceutical company’s stock valued at $372,000 after purchasing an additional 2,403 shares during the period.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Featured Story: Closed-End Mutual Funds (CEFs)

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply